Detailed Discussion on the Latest Issues in COVID-19 Rebound, Omicron Subvariants BA.4 and BA.5, Current and Next Generation COVID-19 Vaccines, Pediatric Vaccine Rollout, Monkeypox, and More

Program Description

The IAS–USA COVID-19 Dialogues bring together leading experts to discuss what the data and research are telling us about the basic science, public health, and clinical aspects of COVID-19 and the consequences of the pandemic.

This Dialogue will provide a robust and relevant discussion of COVID-19 and SARS-CoV-2 at the time. Note, Dialogues are intended for healthcare clinicians and researchers.

• COVID-19 rebound after COVID-19 oral antiviral therapy
• The emergence of Omicron subvariants BA.4 and BA.5: Why they are different and what they mean for vaccines and the pandemic
• Current and next-generation vaccines
• Pediatric vaccines rollout in infants and their current uptake
• Monkeypox: Endemic or episodic outbreaks?
• New COVID-19 drugs

Recent Articles and Resources:

• Oral Sabizabulin for High-Risk, Hospitalized Adults with Covid-19: Interim Analysis
• Mosaic RBD Nanoparticles Protect Against Challenge by Diverse Sarbecoviruses in Animal Models
• Demographic and Clinical Characteristics of Confirmed Human Monkeypox Virus Cases in Individuals Attending a Sexual Health Centre in London, UK: An Observational Analysis
• CDC’s Monkeypox Update
• Situational Awareness: Monkeypox Outbreak—United States, June 2022
• NYC Health Department’s Interim Guidance for Treatment of Monkeypox

Sign Up

Please use the following link to sign up https://us06web.zoom.us/webinar/register/WN_SJqKDd5pSl6GUeTW1HSzvQ or click the button below.

Zoom will send an email that includes a unique link to join the Zoom activity and allow you to add this information to your calendar. Zoom will send 1-day and 1-hour reminders.

Sign Up